30
Participants
Start Date
March 15, 2019
Primary Completion Date
January 31, 2020
Study Completion Date
July 31, 2020
Aminoven 10%
"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care."
RENORAL
"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care."
RECRUITING
Hopital Center, Dunkirk
Lead Sponsor
Collaborators (1)
BioFortis
OTHER
Indigo Therapeutics
INDUSTRY